Literature DB >> 22302684

Increased radioresistance via G12S K-Ras by compensatory upregulation of MAPK and PI3K pathways in epithelial cancer.

Annette Affolter1, Martynas Drigotas, Kai Fruth, Irene Schmidtmann, Christoph Brochhausen, Wolf J Mann, Jürgen Brieger.   

Abstract

BACKGROUND: Irradiation-induced signaling via the 2 pathways, Raf-MEK-ERK and PI3K-Akt, is known to be closely associated with a limited response to radiotherapy. In the present study we analyzed the relevance of constitutively active K-Ras for postradiogenic pathway stimulation and the option of coordinated inhibition to overcome these rescue mechanisms.
METHODS: We used 2 epithelial tumor cell lines as a model system, one of them harboring a G12S K-Ras mutation. Cells were irradiated and the effect of combined treatment with ionizing radiation and inhibitors on the expression of pERK and pAkt was determined by Western blotting. Additionally, clonogenic assays were performed to functionally analyze survival of the cell lines.
RESULTS: Compared with the nonmutated cells we observed the G12S cell line showing a clearly reduced response to inhibitor treatment under irradiation. In the case of pharmacologic inhibition of 1 of the pathways a compensatory upregulation of the second cascade leading to increased clonogenic survival seems feasible. However, there was a good functional response of this cell line to double inhibition with both compounds represented by minimized colony forming ability. The activation of ERK and Akt after irradiation was confirmed in xenotransplants showing elevated postradiogenic protein levels.
CONCLUSION: With our data we confirmed our hypothesis of postradiogenic constitutive activation of the 2 pathways both required for Ras-mediated radioresistance in epithelial cells. If this effect should prove itself as a general mechanism in Ras-mutated tumors, application of specific inhibitors to block both cascades in parallel could contribute to enhance radiosensitivity in these types of cancer.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22302684     DOI: 10.1002/hed.22954

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  14 in total

1.  Cooperative effect of BI-69A11 and celecoxib enhances radiosensitization by modulating DNA damage repair in colon carcinoma.

Authors:  Ipsita Pal; Kaushik Kumar Dey; Madhuri Chaurasia; Sheetal Parida; Subhayan Das; Y Rajesh; Kulbhushan Sharma; Tamohan Chowdhury; Mahitosh Mandal
Journal:  Tumour Biol       Date:  2015-12-02

2.  Mitogen-activated protein kinase inhibition-induced modulation of epidermal growth factor receptor signaling in human head and neck squamous cell carcinoma.

Authors:  Guiqin Xie; Ailin Zhu; Xinbin Gu
Journal:  Head Neck       Date:  2021-02-03       Impact factor: 3.821

3.  Mutant KRAS associated malic enzyme 1 expression is a predictive marker for radiation therapy response in non-small cell lung cancer.

Authors:  Gaurab Chakrabarti
Journal:  Radiat Oncol       Date:  2015-07-16       Impact factor: 3.481

4.  Ultra-deep targeted sequencing of advanced oral squamous cell carcinoma identifies a mutation-based prognostic gene signature.

Authors:  Shu-Jen Chen; Hsuan Liu; Chun-Ta Liao; Po-Jung Huang; Yi Huang; An Hsu; Petrus Tang; Yu-Sun Chang; Hua-Chien Chen; Tzu-Chen Yen
Journal:  Oncotarget       Date:  2015-07-20

Review 5.  The role of the dysfunctional akt-related pathway in cancer: establishment and maintenance of a malignant cell phenotype, resistance to therapy, and future strategies for drug development.

Authors:  Gaetano Romano
Journal:  Scientifica (Cairo)       Date:  2013-12-05

6.  Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer.

Authors:  Mahmoud Toulany; Mari Iida; Simone Keinath; Firdevs F Iyi; Katharina Mueck; Birgit Fehrenbacher; Wael Y Mansour; Martin Schaller; Deric L Wheeler; H Peter Rodemann
Journal:  Oncotarget       Date:  2016-07-12

7.  Adaptive ERK signalling activation in response to therapy and in silico prognostic evaluation of EGFR-MAPK in HNSCC.

Authors:  Chao Rong; Marie F Muller; Fang Xiang; Alexandra Jensen; Wilko Weichert; Gerald Major; Peter K Plinkert; Jochen Hess; Annette Affolter
Journal:  Br J Cancer       Date:  2020-05-19       Impact factor: 7.640

8.  Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy.

Authors:  Ke Xu; Dongkyoo Park; Andrew T Magis; Jun Zhang; Wei Zhou; Gabriel L Sica; Suresh S Ramalingam; Walter J Curran; Xingming Deng
Journal:  Mol Cancer       Date:  2019-04-10       Impact factor: 27.401

9.  Mcl-1 Interacts with Akt to Promote Lung Cancer Progression.

Authors:  Guo Chen; Dongkyoo Park; Andrew T Magis; Madhusmita Behera; Suresh S Ramalingam; Taofeek K Owonikoko; Gabriel L Sica; Keqiang Ye; Chao Zhang; Zhengjia Chen; Walter J Curran; Xingming Deng
Journal:  Cancer Res       Date:  2019-10-29       Impact factor: 12.701

Review 10.  Targeting the AKT pathway: Repositioning HIV protease inhibitors as radiosensitizers.

Authors:  Jayant S Goda; Tejaswini Pachpor; Trinanjan Basu; Supriya Chopra; Vikram Gota
Journal:  Indian J Med Res       Date:  2016-02       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.